meiosis regulator for oocyte developmentGenealiases: MIO · Sea4 · Yulink
Q-omics provides the consensus-scored MIOS profile across patient tissues and cancer cell-line models. MIOS expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MIOS is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, MIOS RNA expression shows 19,405 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, COAD, and UVM as cancer lineages where MIOS shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIOS — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIOS survival associations across molecular data types. MIOS RNA expression shows survival associations in the most cancer types (28), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIOS RNA expression–survival associations across cancer types. High MIOS expression shows unfavorable associations in CESC, LGG, OV and LIHC, but favorable associations in KIRC and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MIOS RNA expression.
This table summarizes MIOS tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for MIOS. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIOS shows lower tumor expression in THCA and higher tumor expression in COAD, LUAD, BLCA, KIRC and CHOL. The COAD box plot shows higher MIOS RNA expression in tumor versus normal tissue (log2 FC = +0.658, t-test p < 0.001).
This table shows molecular features associated with MIOS in patient tissues and cancer cell lines. In patient samples, MIOS shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, MIOS RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
